Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Vertex Pharmaceuticals

(

VRTX

) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Vertex Pharmaceuticals rose $4.75 (6.1%) to $83.14 on average volume. Throughout the day, 2,401,246 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2,544,600 shares. The stock ranged in a price between $78.26-$83.94 after having opened the day at $78.43 as compared to the previous trading day's close of $78.39. Other companies within the Health Care sector that increased today were:

EnteroMedics

(

ETRM

), up 30.8%,

Lakeland Industries

(

LAKE

), up 16.4%,

IsoRay

(

ISR

), up 15.0% and

Affymax

(

AFFY

), up 14.6%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.3 billion and is part of the drugs industry. Shares are up 86.2% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

On the negative front,

ARCA biopharma

(

ABIO

), down 30.9%,

Kips Bay Medical

(

KIPS

), down 14.0%,

Genvec

(

GNVC

), down 12.1% and

TG Therapeutics

(

TGTX

), down 11.3%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null